Servier Data Presented at AACR Underscores Unwavering Dedication to Advancing Oncology R&D
Improving the lives of our patients
We work tirelessly to deliver meaningful therapeutics for the patients we serve.
Servier Data Presented at AACR Underscores Unwavering Dedication to Advancing Oncology R&D
Servier receives a positive CHMP opinion for ONIVYDE® in combination with oxaliplatin, fluorouracil and leucovorin (NALIRIFOX) as first line therapy in patients with metastatic pancreatic adenocarcinoma.
Servier Receives Regulatory Filing Acceptances from FDA and EMA for Vorasidenib in the Treatment of IDH-Mutant Diffuse Glioma